

Seborrheic Dermatitis

Background

1. Definition

- Common condition of skin regions rich in sebaceous glands characterized by flaking, erythema, itching
- May present at all ages
- In infants often presents as "Cradle cap" on the scalp and in adults as a rash in the nasolabial folds and brows, chest, axilla, under breasts, around the umbilicus or scalp

Pathophysiology

1. Pathology of disease

- Etiology unknown but several hypotheses
 - Fungal infection
 - Causal relationship with yeasts *Malassezia furfur* and *Malassezia ovalis*
 - Also associated with HIV/AIDS
 - Hormone levels
 - Correlated with infancy and re-appearance at puberty
 - Nutritional
 - Mechanism unclear
 - Altered fatty acid pattern
 - Associated with infantile variant
 - Neurogenic factors
 - Higher percentages in those with Parkinsonism, post-CVA, epilepsy, CNS trauma, facial nerve palsy, syringomyelia

2. Incidence, prevalence

- Men > women
- Infants < 6 months (usually)
- Adolescents, young adults; adults 30-60 years
- 1-3% in immunocompetent adults
- Underreported in mild cases

3. Risk factors

- Unrelated to personal cleanliness

4. Morbidity / mortality

- Psychosocial is primary morbidity in most
 - Secondary infection may produce weeping dermatitis/crusting
 - If involves 90% or more of body referred to as erythroderma or exfoliative dermatitis
 - Erythroderma Desquamativum (Leiner's disease)
 - Severe seborrheic dermatitis with diarrhea and lymphadenopathy in infants
 - Check for immunodeficiencies (SOR:C)¹

Diagnostics

1. History
 - Itching, scaling, burning (active phase)
 - More in winter, early spring; followed by inactive period, in characteristic locations
2. Physical exam
 - Red, flaky greasy appearance in scalp (dandruff), eyebrows, lid margins (blepharitis), behind ears, nasolabial folds, pre-sternal, axilla, navel, groin, infra-mammary, anogenital; hypopigmentation in blacks; symmetric distribution
 - 2 rash types on chest
 - Petaloid
 - Reddish brown, follicular, and peri-follicular papules with greasy scales
 - Papules may expand to flower-petal shaped patches
 - Pityriasiform (less common)
 - Generalized macules and patches, common on trunk and neck, similar to pityriasis rosea
 - Infantile
 - 2nd week - 6 months (or longer)
 - Scalp (cradle cap = pityriasis capitis), face, ears, flexural folds
 - Symptoms mild
 - Resolves with time on own in most
3. Diagnostic testing
 - Usually not required
 - If in doubt, skin scraping/biopsy to rule out tinea infection although often responds to topical antifungals anyway

Differential Diagnosis

1. Scalp
 - Tinea capitis, psoriasis, infected eczema
2. Face
 - Rosacea, facial chapping, SLE
3. Body
 - Atopic eczema, psoriasis, tinea versicolor, drug eruptions, candidiasis (groin), staph blepharitis
4. Infants
 - Atopic eczema, scabies, psoriasis, irritant contact dermatitis

Therapeutics

1. High recurrence rate, goal is most often control, not cure
 - If severe/widespread, assess if diagnosis correct or if patient immunocompromised
2. Infants
 - Will spontaneously resolve in wks-months

- Overnight soak with baby oil, white petroleum jelly; wash with baby shampoo
- If ineffective, ketoconazole 2% cream once daily
 - Ketoconazole appears to be safe and efficacious for infants with cradle cap
 - Other OTC topical antifungals also likely effective.
- Topical steroids not advised other than possibly briefly for diaper areas
- 3. Adults and adolescents
 - Scalp and beard
 - Tx may include topical keratolytics, antifungals and steroidal creams/liniments
 - Antifungals (2-3 times/wk for 2-4 weeks)
 - Ketoconazole 2%
 - Clotrimazole 1%
 - Selenium sulfide 1% (Selsun Blue) or 2.5% (Exsel, Sesun)^{2,3}
 - Keratolytics (2-3 times/wk initially then as needed)
 - Coal tar (DHS Tar, Zetar, Ionil T Plus)
 - Salicylic acid 2% cream/gel/lotion/shampoo (Fostex, Stidex)
 - Sulfur 2-3% cream/lotion/shampoo
 - Pyrithione zinc 1% (Dandrex, Zincon, Head & Shoulders) and 2% (DHS Zinc, Sebulon)
 - Patient should leave in hair at least 5 mins to ensure these agents get deep into scalp
 - Warm mineral oil with combing of crusts also used.
 - Topical steroids/liniments (2-4 wks)
 - Shampoo (fluocinolone, twice weekly)
 - Steroid solutions (fluocinolone, once daily)
 - Lotion (betamethasone valerate, once daily)
 - Cream (desonide, once daily)
 - Effective in treatment of adult seborrheic dermatitis of scalp (SOR:C)^{1,4}
 - Face and body
 - Antifungal shampoos (listed above) can be used frequently on affected areas
 - Ketoconazole 2% cream, 1-2/day for 4 wks or until clinical clearing
 - Consider mild corticosteroid cream to settle inflammation quickly
 - Ketoconazole qD topically with desonide qD for 2 weeks may be useful for facial dermatitis
 - Topical calcineurin inhibitors (eg tacrolimus ointment, pimecrolimus cream) for face, ears once daily; have fungicidal and anti-inflammatory properties
 - Daily use for 1 week necessary before benefits seen (SOR:B)¹
 - Blepharitis
 - Gentle cleansing of eyelid margin twice daily with cotton swab dipped in 1/2 cup warm water containing 2-3 drops baby shampoo

Follow-Up

1. F/U if poor response to treatment, worsening symptoms, infection
2. Refer to specialist
 - Severe, widespread
 - Diagnostic uncertainty
 - No response to treatment

Patient Education

1. <http://familydoctor.org/online/famdocen/home/common/skin/disorders/157.html>

Evidence-Based Inquiry

1. What is the best treatment for cradle cap?

References

1. Schwartz RA, Janusz CA, Janniger CK. Seborrheic Dermatitis: An Overview. Am Fam Physician 2006;74:125-30. <http://www.aafp.org/afp/20060701/125.html>. Accessed 10.26.2008.
2. Johnson BA, Nunley JR. Treatment of Seborrheic Dermatitis. Am Fam Physician 2000;61:2703-10. <http://www.aafp.org/afp/20000501/2703.html> Accessed 10.26.2008.
3. National Guideline Clearinghouse (NGC). Guideline summary: Seborrheic Dermatitis. In National Guideline Clearinghouse (NGC) [http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=11044&nbr=5823]. Rockville (MD): [cited 2008 October 26] Available: <http://guideline.gov>.
4. Manriquez JJ, Uribe P. Seborrheic dermatitis. Clin Evid 2006;16:670-2.

Author: Anu Kompella, MD, *Michigan State University-Sparrow Hospital FPRP*

Editor: Vince WinklerPrins, MD, *Georgetown University-Providence Hospital, Washington DC*